Synthesis, Structural Elucidation and Pharmacological Applications of Cu(II) Heteroleptic Carboxylates
Six heteroleptic Cu(II) carboxylates (<b>1</b>-<b>6</b>) were prepared by reacting 2-chlorophenyl acetic acid (<b>L<sup>1</sup></b>), 3-chlorophenyl acetic acid (<b>L<sup>2</sup></b>), and substituted pyridine (2-cyanopyridine a...
Saved in:
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Six heteroleptic Cu(II) carboxylates (<b>1</b>-<b>6</b>) were prepared by reacting 2-chlorophenyl acetic acid (<b>L<sup>1</sup></b>), 3-chlorophenyl acetic acid (<b>L<sup>2</sup></b>), and substituted pyridine (2-cyanopyridine and 2-chlorocyanopyridine). The solid-state behavior of the complexes was described via vibrational spectroscopy (FT-IR), which revealed that the carboxylate moieties adopted different coordination modes around the Cu(II) center. A paddlewheel dinuclear structure with distorted square pyramidal geometry was elucidated from the crystal data for complexes <b>2</b> and <b>5</b> with substituted pyridine moieties at the axial positions. The presence of irreversible metal-centered oxidation reduction peaks confirms the electroactive nature of the complexes. A relatively higher binding affinity was observed for the interaction of SS-DNA with complexes <b>2</b>-<b>6</b> compared to <b>L<sup>1</sup></b> and <b>L<sup>2</sup></b>. The findings of the DNA interaction study indicate an intercalative mode of interaction. The maximum inhibition against acetylcholinesterase enzyme was caused for complex <b>2</b> (IC<sub>50</sub> = 2 µg/mL) compared to the standard drug Glutamine (IC<sub>50</sub> = 2.10 µg/mL) while the maximum inhibition was found for butyrylcholinesterase enzyme by complex <b>4</b> (IC<sub>50</sub> = 3 µg/mL) compared to the standard drug Glutamine (IC<sub>50</sub> = 3.40 µg/mL). The findings of the enzymatic activity suggest that the under study compounds have potential for curing of Alzheimer's disease. Similarly, complexes <b>2</b> and <b>4</b> possess the maximum inhibition as revealed from the free radical scavenging activity performed against DPPH and H<sub>2</sub>O<sub>2</sub>. |
---|---|
Item Description: | 10.3390/ph16050693 1424-8247 |